Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations

References

• Howlader MillerDBishopKProstate cancer SEER cancerStat Rev201719752014
   Google Scholar
• SiegelRLMillerKDJemalACancer Statistics, 2017CA Cancer J Clin201767173028055103
   PubMed Web of Science ®Google Scholar
• BergKDThomsenFBMikkelsenMKIngimarsdóttirIJHansenRBKejsAMBrassoKImproved survival for patients with de novo metastatic prostate cancer in the last 20 yearsEur J Cancer201772202728024263
   PubMed Web of Science ®Google Scholar
• HugginsCEffect of orchiectomy and irradiation on cancer of the prostateAnn Surg194211561192120017858048
   PubMedGoogle Scholar
• WadoskyKMKoochekpourSMolecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancerOncotarget2016739644476447027487144
   PubMedGoogle Scholar
• FizaziKTranNFeinLAbiraterone plus prednisone in metastatic, castration-sensitive prostate cancerN Engl J Med2017377435236028578607
   PubMed Web of Science ®Google Scholar
• JamesNDde BonoJSSpearsMRSTAMPEDE InvestigatorsAbiraterone for prostate cancer not previously treated with hormone therapyN Engl J Med2017377433835128578639
   PubMed Web of Science ®Google Scholar
• ScottLJAbiraterone acetate: a review in metastatic castration-resistant prostrate cancerDrugs201777141565157628819727
   PubMed Web of Science ®Google Scholar
• FizaziKScherHIMolinaACOU-AA-301 InvestigatorsAbiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyLancet Oncol2012131098399222995653
   PubMed Web of Science ®Google Scholar
• RyanCJSmithMRFizaziKCOU-AA-302 InvestigatorsAbiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 studyLancet Oncol201516215216025601341
   PubMed Web of Science ®Google Scholar
• JamesNDSpearsMRSydesMRAbiraterone in metastatic prostate cancerN Engl J Med20173771696169729069563
   PubMedGoogle Scholar
• JamesNDSydesMRClarkeNWSTAMPEDE investigatorsAddition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialLancet2016387100241163117726719232
   PubMed Web of Science ®Google Scholar
• SpearsMRJamesNDSydesMR‘Thursday’s child has far to go’-interpreting subgroups and the STAMPEDE trialAnn Oncol201728102327233028961849
   PubMed Web of Science ®Google Scholar
• RydzewskaLHMBurdettSValeCLSTOPCaP Abiraterone CollaboratorsAdding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysisEur J Cancer2017848810128800492
   PubMed Web of Science ®Google Scholar
• SweeneyCJChenYHCarducciMChemohormonal therapy in metastatic hormone-sensitive prostate cancerN Engl J Med2015373873774626244877
   PubMed Web of Science ®Google Scholar
• WallisCJDKlaassenZBhindiBComparison of abirater-one acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-naïve prostate cancer: a systematic review and network meta-analysisEur Urol201873683484429037513
   PubMed Web of Science ®Google Scholar
• SydesMRSpearsMRMasonMDSTAMPEDE InvestigatorsAdding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocolAnn Oncol20182951235124829529169
   PubMed Web of Science ®Google Scholar
• ValeCLFisherDJCarpenterJWhat are the optimal systemic treatments for men with metastatic, hormone-sensitive prostate cancer? A STOPCaP systematic review and network meta-analysisAnn Oncol201728suppl 512491257
   Google Scholar
• TanPSAguiarPHaalandBLopesGAddition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysisProstate Cancer Prostatic Dis2018136
   Google Scholar
• Abdel-RahmanOCheungWYImpact of prior local treatment on the outcomes of metastatic hormone-sensitive prostate cancer: secondary analysis of a randomized controlled trialClin Genitourin Cancer Epub2018721
   Web of Science ®Google Scholar
• XuLPachynskiRKContemporary management of the newly diagnosed prostate cancer patient with metastatic disease at presentationCurr Urol Rep201819107930105573
   PubMed Web of Science ®Google Scholar
• AggarwalRAbiraterone or docetaxel plus androgen deprivation in hormone-sensitive prostate cancer: more questions than answersEur Urol201873684584629128209
   PubMed Web of Science ®Google Scholar
• de BonoJSLogothetisCJMolinaACOU-AA-301 InvestigatorsAbiraterone and increased survival in metastatic prostate cancerN Engl J Med2011364211995200521612468
   PubMed Web of Science ®Google Scholar
• RyanCJSmithMRde BonoJSCOU-AA-302 InvestigatorsAbiraterone in metastatic prostate cancer without previous chemotherapyN Engl J Med2013368213814823228172
   PubMed Web of Science ®Google Scholar
• MottetNBJBriersEMembers of the EAU – ESTRO – ESUR –SIOG Prostate Cancer Guidelines PanelEAU – ESTRO – ESUR – SIOG Guidelines on Prostate Cancer Available from: https://uroweb.org/guideline/prostate-cancer/Accessed August 2, 2018
   Google Scholar
• American Urological Association. Clinically Localized Prostate CancerAUA/ASTRO/SUO Guidelines2017 Available from: http://www.auanet.org/guidelines/prostate-cancer-clinically-localizedAccessed August 2, 2018
   Google Scholar
• National Comprehensive Cancer Network: (NCCN) Prostate Cancer (Version 4.2018)National Comprehensive Cancer Network2018 Available from: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdfAccessed August 2, 2018
   Google Scholar
• MorrisMJRumbleRBBaschEOptimizing anticancer therapy in metastatic non-castrate prostate cancer: American society of clinical oncology clinical practice guidelineJ Clin Oncol201836151521153929608397
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug AdministrationFDA approves abiraterone acetate in combination with prednisone for high-risk metastatic castration-sensitive prostate cancerFDA2018 Available from: www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm596015.htmAccessed August 2, 2018
   Google Scholar
• ChiKNProtheroeARodríguez-AntolínAPatient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trialLancet Oncol201819219420629326030
   PubMed Web of Science ®Google Scholar
• HugginsCBergenstalDMEffect of bilateral adrenalectomy on certain human tumorsProc Natl Acad Sci U S A1952381737616589057
   PubMed Web of Science ®Google Scholar
• HugginsCStudies on prostatic cancerArch Surg1941432209
   Google Scholar
• TannockIFde WitRBerryWRTAX 327 Investigators. Doc-etaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerN Engl J Med2004351151502151215470213
   PubMed Web of Science ®Google Scholar
• McNamaraMSweeneyCAntonarakisESArmstrongAJThe evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivationProstate Cancer Prostatic Dis201821330631829263421
   PubMed Web of Science ®Google Scholar
• DamodaranSKyriakopoulosCEJarrardDFNewly diagnosed metastatic prostate cancer: has the paradigm changed?Urol Clin North Am201744461162129107277
   PubMed Web of Science ®Google Scholar
• MalaspinaSde GiorgiUKemppainenJdel SoleAPaganelliG68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancerRadiol Med Epub2018816
   Web of Science ®Google Scholar
• LenganaTLawalIOBoshomaneTG68Ga-PSMA PET/CT replacing bone scan in the initial staging of skeletal metastasis in prostate cancer: a fait accompli?Clin Genitourin Cancer201816539240130120038
   PubMed Web of Science ®Google Scholar
• van SoestRJde WitRIrrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trialsBMC Med20151330426695172
   PubMed Web of Science ®Google Scholar
• WallisCJDSatkunasivamRSaskinRBansalSKulkarniGSEmmeneggerUNamRKPopulation-based analysis of treatment toxicity among men with castration-resistant prostate cancer: a Phase IV studyUrology201811313814529191639
   PubMed Web of Science ®Google Scholar
• CindoloLNatoliCDe NunzioCSafety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter “real life” studyBMC Cancer201717175329126389
   PubMed Web of Science ®Google Scholar
• McGrathMJBingeLCSriratanaARegulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancerCancer Res201373165066507923801747
   PubMed Web of Science ®Google Scholar
• HörnbergEYlitaloEBCrnalicSExpression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survivalPLoS One201164e1905921552559
   PubMed Web of Science ®Google Scholar
• AntonarakisESLuCWangHAR-V7 and resistance to enzalutamide and abiraterone in prostate cancerN Engl J Med2014371111028103825184630
   PubMed Web of Science ®Google Scholar
• NyquistMDDehmSMInterplay between genomic alterations and androgen receptor signaling during prostate cancer development and progressionHorm Cancer201342616923307762
   PubMed Web of Science ®Google Scholar
• CoutinhoIDayTKTilleyWDSelthLAAndrogen receptor signaling in castration-resistant prostate cancer: a lesson in persistenceEndocr Relat Cancer20162312T179T19727799360
   PubMed Web of Science ®Google Scholar
• GourdinTRecent advances in the management of metastatic prostate cancer: optimizing use of existing therapies, while searching for novel interventionsCurr Opin Oncol201830315916429553949
   PubMed Web of Science ®Google Scholar
• KomuraKSweeneyCJInamotoTIbukiNAzumaHKantoffPWCurrent treatment strategies for advanced prostate cancerInt J Urol201825322023129266472
   PubMed Web of Science ®Google Scholar
• UNICANCERA Phase III of ADT + Docetaxel +/− Local RT +/− Abiraterone Acetate in Metastatic Hormone-Naïve Prostate Cancer (PEACE1) Available from: https://clinicaltrials.gov/ct2/show/NCT01957436.NLMidentifier:NCT01957436AccessedAugust 16, 2018
   Google Scholar